For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Syros Pharmaceuticals Inc’s stock clocked out at $0.20, down -0.89% from its previous closing price of $0.20. In other words, the price has decreased by -$0.89 from its previous closing price. On the day, 2.83 million shares were traded. SYRS stock price reached its highest trading level at $0.22 during the session, while it also had its lowest trading level at $0.2.
Ratios:
To gain a deeper understanding of SYRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.25 and its Current Ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on November 04, 2020, Upgraded its rating to Buy and sets its target price to $15 from $11 previously.
On September 22, 2020, Alliance Global Partners started tracking the stock assigning a Buy rating and target price of $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when Flagship VentureLabs IV LLC bought 21,333 shares for $0.23 per share.
Flagship Pioneering Fund VII, bought 1,000,000 shares of SYRS for $230,000 on Dec 13 ’24. On Dec 13 ’24, another insider, Flagship Ventures Fund IV-RX, , who serves as the Affiliate of the company, bought 55,925 shares for $0.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRS now has a Market Capitalization of 5366500 and an Enterprise Value of 7317491. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.65. Its current Enterprise Value per Revenue stands at 18.957 whereas that against EBITDA is -0.066.
Stock Price History:
Over the past 52 weeks, SYRS has reached a high of $8.17, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -83.31%, while the 200-Day Moving Average is calculated to be -94.52%.
Shares Statistics:
It appears that SYRS traded 8.39M shares on average per day over the past three months and 2019970 shares per day over the past ten days. A total of 26.83M shares are outstanding, with a floating share count of 17.43M. Insiders hold about 35.03% of the company’s shares, while institutions hold 36.36% stake in the company. Shares short for SYRS as of 1732838400 were 2234994 with a Short Ratio of 0.27, compared to 1730332800 on 1248537. Therefore, it implies a Short% of Shares Outstanding of 2234994 and a Short% of Float of 9.060001.
